Floatz logo

Eflornithine

Glioblastoma, IDH-Wildtype

Mayo ClinicSmall moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

39 Active assets in the Glioblastoma, IDH-Wildtype cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Ipilimumab
Neonc Technologies, Inc.
Phase 2B
Cerebraca Wafer
Everfront Biotech Co., Ltd.
Phase 2/3B

View all 44 →

Same molecule, other indications

Eflornithine is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
66 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
64 / 100
View asset →
colon adenomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →